The Korea Disease Control and Prevention Agency (KDCA) announced that they will focus on securing national budget to develop Korea-made mRNA vaccines and secure platforms, supporting up to phase 3 trials.

Its vision is to secure domestic mRNA technology based on Japan's case. Japan designated companies that could develop domestic vaccines during the COVID-19 pandemic from 2020 to 2023 and invested KRW 930 billion in the entire process from the beginning of the development, clinical trials, and production.

The KDCA has submitted this plan to the Health and Welfare Committee of the National Assembly on July 24th. The KDCA explained that they set a government-wide policy to develop mRNA va